1. Short title This Act may be cited as the PFAS Accountability Act of 2024 . 2. Findings Congress finds that— (1) the Centers for Disease Control and Prevention has detected numerous perfluoroalkyl and polyfluoroalkyl substances (referred to in this Act as PFAS ) in the blood serum of individuals in the United States, all of which come from manufacturing and use of PFAS by humans, as there is no natural source of PFAS in human blood; (2) peer-reviewed studies by other organizations have detected PFAS in the drinking water of at least 200,000,000 individuals in the United States; (3) PFAS are introduced into the market every year, and little research is conducted to ensure the safety of PFAS for individuals; (4) as of the day before the date of enactment of this Act, a Federal statutory cause of action does not exist for individuals harmed by the long-term effects of PFAS exposure; and (5) PFAS exposure, even at low levels, has been linked to chronic diseases, including cancer, reproductive and developmental harms, and harms to the immune system. 3. Purposes The purposes of this Act are— (1) to encourage PFAS research and provide accountability for irresponsible PFAS manufacturing and irresponsible use of PFAS in manufacturing by codifying— (A) a Federal cause of action for individuals significantly exposed to PFAS; and (B) a medical monitoring remedy for those individuals; (2) to help address harm to individuals significantly exposed to PFAS by— (A) codifying that harm as an injury at law and equity; and (B) shifting the costs of medical monitoring from those individuals to the parties responsible for the exposure